Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERALD: CVnCoV Vaccine Efficacy in COVID-19
NCT04652102Phase 3Completed
- Sponsor
- CureVac
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 10
01
Overview
A Phase 3 trial of zorecimeran in coronavirus disease 2019 (COVID-19), sponsored by CureVac. Started Dec 2020; status: completed.
02
Drugs
zorecimeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04652102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652102.